![Seung Suh Hong](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Seung Suh Hong
Director/Board Member at OCULAR THERAPEUTIX, INC.
Net worth: 50 918 $ as of 31/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Amit Chunilal Nathwani | M | 64 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 5 years |
Donald Notman | M | 64 | 7 years | |
Charles Warden | M | 55 | 16 years | |
Scott Corning | M | - | 14 years | |
Jeffrey S. Heier | M | 63 | 9 years | |
Richard Lindstrom | M | 76 | 12 years | |
Merilee Raines | F | 68 | 3 years | |
Leslie Williams | F | 64 | 5 years | |
Ha-Chul Kim | M | - |
Cellemedy Co., Ltd.
![]() Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Cellemedy Co., Ltd. develops next-generation cancer treatments to improve the health of people suffering from cancer. The company is based in Seongnam-si, South Korea. The South Korean company was founded in 2016. The CEO is Ha-Chul Kim. | - |
Nilesh Modi | M | 55 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Han-Gi Lee | M | 47 | 13 years | |
Brian Silver | M | 55 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Simon Aron Goldman | M | 45 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Tracy Smith | F | - | 4 years | |
Bharat Kumar Hirji Thakrar | M | 67 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Karen-Leigh Edwards | M | - | 3 years | |
Scott Clarke | M | - |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 1 years |
Adrienne Graves | M | 69 | 1 years | |
Samit Govindji Hathi | M | 57 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Pravin Dugel | M | 60 | - | |
Richard Fagan | M | 63 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Pauline Jen Ryan | F | - | - | |
Peter K. Kaiser | M | - | - | |
Michael Owen | M | 73 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 1 years |
Philip Strassburger | M | 64 | 4 years | |
Christopher White | M | 62 | 5 years | |
Peter Jarrett | M | - | 17 years | |
Sanjay Nayak | M | 54 | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Amarpreet S. Sawhney | M | 57 | 13 years | |
Antony Mattessich | M | 57 | 7 years | |
Jim O'Shea | M | 74 | 4 years | |
Bruce Peacock | M | 72 | 8 years | |
Daniel M. Bollag | M | 63 | 2 years | |
Jaswinder S. Chadha | M | 56 | 6 years | |
Geun-Kyung Lee | M | 66 | - | |
Jeong-Soo Suh | M | 64 | - | |
Kwang-Young Moon | M | 58 | - | |
Rabia Ozden | M | 56 | 3 years | |
Kevin Hanley | M | 62 | 2 years | |
Nicole Carta | F | - | - | |
Chad Brines | M | - | 4 years | |
Patricia Kitchen | F | 46 | 2 years | |
Amar Sawhney | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 29 | 67.44% |
United Kingdom | 9 | 20.93% |
South Korea | 5 | 11.63% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Seung Suh Hong
- Personal Network